A big pharma company just slashed the price of its insulin by 50%, but people are worried the $137-per-vial price tag is still unaffordable

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 37 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 51%

España Noticias Noticias

España Últimas Noticias,España Titulares

A big pharma company just slashed the price of its insulin by 50%, but people are worried the $137-per-vial price tag is still unaffordable.

" version of the medication, and sell it for half the price of the branded drug. An authorized generic is identical to the original drug, but it will have different packaging or labeling.

To her, that price tag is still unaffordable for people who are uninsured or have an insurance plan that requires them to pay the full list price for insulin.People who do have health insurance likely pay an amount that's less than the full list price of Humalog. They may pay a fixed amount of money or aof the drug each time they go to the pharmacy.

The goal of the authorized generic is to offer those patients, as well as those who are uninsured, a lower list price at the pharmacy counter. "It would be very disruptive for one company or the entire system to move to a different model overnight," Mason said."It's something that's going to have to require an evolution to get there."

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

 /  🏆 729. in ES
 

Gracias por tu comentario. Tu comentario será publicado después de ser revisado.

Price still too high. This price drop still gives company huge profit!

What is the profit margin on this stuff?

Profit Margin Caps are needed for all pharma.

Good news, but still a scam by Eli Lilly.

I give them credit for the improvement, though.

You THINK!!!

España Últimas Noticias, España Titulares